

MINUTES

Barth Syndrome Foundation, Inc. Board of Directors Meeting October 18, 2017

Chairman

Members in Attendance:

Marcus E. Sernel David Axelrod, MD Matthew Blumenthal B.J. Develle Nicole Derusha-Mackey Florence Mannes Susan A. McCormack Susan Osnos John Wilkins Kevin Woodward Stephen B. McCurdy Lindsay Groff, Executive Director

Board Member Treasurer, Board Member Chairman *Emeritus* Board Member, *ex-officio*

Members Not in Attendance/Partial Attendance

Catharine Lynne Ritter

Invited Guests:

Lynda Sedefian, Executive Assistant Kate McCurdy, *Emerita*, SMAB

Our Mission - Saving lives through education, advances in treatment, and finding a cure for Barth syndrome.

Board Member

Agenda Items:

- 1. Ratification of Minutes
- 2. Review & Discussion Financials
- 3. Review & Discussion Operations
- 4. Review & Discussion Fundraising
- 5. Update 2018 Conference
- 6. Update & Discussion Board Development
- 7. Update & Discussion Science/Medicine
- 8. Other

The meeting, held via GoToMeeting, was called to order by the Chairman on Wednesday, October 18, 2017, at 12:00 pm ET.

1. Ratification of Minutes

The April 8, 2017 Board minutes, as submitted on this date. The May 31, 2017 Executive Committee minutes, as submitted on this date. The June 28, 2017 Board minutes, as submitted on this date. The September 27, 2017 Executive Committee minutes, as submitted on this date.

2. <u>Review & Discussion - Financials</u>

Lindsay Groff provided an overview of the August 2017 financial statements, which reflected the following:

<u>Preliminary Statement of Revenue and Expenditures All Funds – 01/01/2017 – 08/31/2017</u> Total Revenues of \$403,293, including unrestricted donations of \$339,343; the balance of \$63,950 is temporarily restricted (Science/Medicine, Varner, and Will McCurdy Funds).

Total Expenses of \$679,394; and a Deficiency of Revenue over Expenditures of \$276,101.

Total Current Assets	\$3,582,130
Total Current Liabilities	\$ 280,696
Total Fund Balance	\$3,301,434

3. <u>Review & Discussion – Operations</u>

Executive Director Position

On September 27, 2017, Lindsay Groff informed the Executive Committee that she will resign her full-time position as Executive Director, on November 3, 2017.

Marc Sernel informed the board that Lindsay has offered to continue to work with BSF in a consultant role through February 9, 2018. After discussion, the board agreed to accept this offer and retain Lindsay in a consultant role beginning November 4, 2017 thru February 9, 2018, to allow for a seamless transition.

VOTE: The board agreed to retain Lindsay Groff in a consulting role starting November 3, 2017 thru February 9, 2018.

Marc Sernel provided an overview of next steps in the process of filling this position. A search committee has been formed, consisting of Marc Sernel, Susan McCormack, Susan Osnos, Kevin Woodward, Kate McCurdy, and Lindsay Groff.*

<u>Felicia Ganote</u>

Lindsay updated the Board that Felicia Ganote, who has consulted with BSF on fundraising strategies the past two years, has resigned from her consulting position due to personal reasons.

4. Review & Discussion - Fundraising

Lindsay Groff provided an overview of fundraising activities, metrics, and the impact on revenue, as well as plans for year-end fundraising activities (i.e., mailed appeals, e-appeals, #GivingTuesday, events, phone calls, etc.). Lindsay informed the board that the NY Islanders will host a Barth Syndrome Night on February 9, 2018.

5. Update – 2018 Conference

Lindsay Groff provided an update on conference planning for BSF's 2018 conference. The Conference Steering Committee consists of all staff members, along with Kevin Woodward, Lois Galbraith, Susan Hone, and Jack Higgins. Preliminary planning is underway (footprint of conference, keynote speaker, theme, etc.). The next meeting is scheduled for November 2, 2017.

6. Update & Discussion – Board Development

Marc Sernel provided an update on proposed candidates for Board membership. A decision was made to invite Megan Branagh to serve on the board for a 3-year term, commencing January 2018.

VOTED: To invite Megan Branagh to serve on the board for a 3-year term, commencing January 2018.

7. Update & Discussion – Science/Medicine

Stealth/Elamipretide

Marc Sernel provided an update on science and medicine initiatives, including an update on the Stealth/Elamipretide clinical trial. Marc informed the board that a meeting was held on October 11, 2017, with members of Stealth and BSF, wherein BSF was provided an update on the progress of this clinical trial.

<u>Bezafibrate</u>

Marc Sernel provided an update on the bezafibrate initiative in the UK. This clinical trial is estimated to start in mid-2018.

Research Grant Program

Marc Sernel provided an overview of the revised grant application process for the grant program.

Request from Dr. Robin Duncan for KO Mice

Marc Sernel informed the board that BSF has received a request from Dr. Robin Duncan for financial assistance to obtain the KO mice from Dr. Strathdee's lab in Glasgow, Scotland. The total cost, which is mainly shipping costs to Canada, is approximately \$2,000. Dr. Duncan has a 2015 BSF Research Grant, but this request for the knock-out (KO) mouse model is beyond the scope of her grant.

VOTED: To allow a budget of up to \$2,000 to assist in the distribution of the KO mouse to Dr. Robin Duncan.

United Mitochondrial Disease Foundation (UMDF) Meeting

Marc Sernel informed the board that ten members of the SMAB, as well Steve McCurdy and Dr. Colin Phoon, attended an off-year SMAB meeting at the UMDF conference in Alexandria, Virginia on June 29, 2017. In addition, an afternoon session of the UMDF meeting was devoted to BTHS research and CL, and this session was well-received. Please see the attached report of that off-year meeting for more details. One recommendation was to have off-year SMAB meetings on a regular basis.

The board will discuss potential new candidates to serve on the Scientific & Medical Advisory Board (SMAB) at the next board meeting in 2018.*

8. Other

Global Genes Meeting

Lindsay Groff informed the board that she and Shelley Bowen attended the Global Genes Meeting held on September 14-16, 2017, where Dr. Colin Steward was awarded the 2017 International RARE Champion of Hope Award. Dr. Steward has dedicated a large portion of his career to helping families with Barth syndrome lead better quality lives.

<u>Website</u>

Lindsay Groff informed the board of the progress of Lynda Sedefian and Shelley Bowen bringing over content to the new website, which is scheduled to go live mid-November.

<u>Adjournment</u>

The Board of Directors adjourned the meeting at 1:40 pm ET. The next Executive Committee meeting is scheduled for Tuesday, December 19, 2017 @ 8:00 pm ET.

Respectfully submitted,

Susalli Mi Come

Susan A. McCormack Secretary